Using AI and sensors to monitor critically ill patients in the ICU
Pervasive Sensing and Artificial Intelligence in Intelligent ICU Subtitles: -Intelligent Intensive Care Unit (I2CU): Pervasive Sensing and Artificial Intelligence for Augmented Clinical Decision-making -ADAPT: Autonomous Delirium Monitoring and Adaptive Prevention
This study is testing whether using AI and sensors can help doctors better monitor and understand the health of critically ill patients in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT05127265 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the assessment of critically ill patients by utilizing advanced sensing technologies and deep learning algorithms. It focuses on capturing vital visual cues related to pain, delirium, and overall patient acuity that are often overlooked due to the demands on nursing staff. By integrating data from accelerometers, video monitoring, and environmental sensors, the study seeks to develop an autonomous system that can accurately predict patient conditions and improve clinical outcomes. The goal is to provide a more objective and continuous assessment of patients' health status in the ICU setting.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 or older who are admitted to the ICU and expected to stay for at least 24 hours.
Not a fit: Patients under 18 years old or those who are on isolation precautions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management and reduced complications for critically ill patients.
How similar studies have performed: While the use of AI and sensor technology in healthcare is gaining traction, this specific approach to monitoring critically ill patients is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 18 or older * admitted to UF Health Shands Gainesville ICU ward * expected to remain in ICU ward for at least 24 hours at time of screening Exclusion Criteria: * under the age of 18 * on any contact/isolation precautions * expected to transfer or discharge from the ICU in 24 hours or less * unable to provide self-consent or has no available proxy/LAR
Where this trial is running
Gainesville, Florida
- University of Florida Health Shands Hospital — Gainesville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Azra Bihorac, MD, MS — University of Florida
- Study coordinator: Andrea E Davidson, BS
- Email: adavidson@ufl.edu
- Phone: 352-294-8723
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.